Tianjin Sets Up Pharmaceutical Innovation And Technology Transfer Center
This article was originally published in PharmAsia News
Executive Summary
Tianjin Institute of Pharmaceutical Research (TIPR), Tianjin Centre for Drug Safety Evaluation and Research, and TIPR Pharmaceutical Responsible Co. Ltd. will jointly set up a pharmaceutical innovation and technology transfer center at the Binhai Hi-Tech Park in Tianjin. The 370-million-yuan ($51.5 million) facility is expected to generate up to 1.5 billion yuan ($208.9 million) of production value for its programs within three years of operation. The center will raise Tianjing city's drug R&D and technical service levels by stimulating beneficial interaction between scientific research and industry. The integration of innovation and technology transfer will greatly spur the development of bioengineering and pharmaceutical industries in the area. (Click here for more - Chinese Language)
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.